Bladder cancer

CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023
Bispecific monoclonal antibody, The Cancer Genome Atlas, Adenocarcinoma, TCGA, TCE, NSCLC, ESMO, IHC, HPV, Data, Head, Bladder cancer, Neck, Neoplasm, Histology, Messenger, Bivalent, Patient, HLA, Vaccine

ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispecific and bivalent antibody fragment-based T-cell engager (TCE) targeting MAGE-A4, an intracellular protein which is presented on HLA-A*02:01 on the surface of cancer cells, at the ESMO Congress 2023, occurring October 20-24 in Madrid, Spain.

Key Points: 
  • The key objective of this study was for CDR-Life to explore MAGE-A4 expression levels in solid tumors using The Cancer Genome Atlas (TCGA) mRNA dataset.
  • In addition, subgroups of high MAGE-A4 expression were present across a wide range of solid cancers including lung adenocarcinoma, ovarian and gastric cancers.
  • “CDR404 is a novel, bispecific and bivalent T-cell engager differentiated from previous solid tumor T-cell engagers targeting MAGE-A4 in the clinic.
  • The MAGE-A4 mRNA distribution profiles across multiple tumor types indicate, that a tumor MAGE-A4 assay will be indispensable for trial screening.

ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, CR, Survival, CIS, FDA, Patient, Bladder cancer, Food, E pluribus unum, Treatment, Vol, Safety, The New England Journal of Medicine, Pivotal trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Literature, Immune system, NK, Massachusetts Medical Society, NEJM, Probability, Case series, PMID, Cystectomy, BCG, NMIBC, BLA, Exception, Vaccine, ImmunityBio COVID-19 vaccine, Tolerability

The BLA is supported by the results of ImmunityBio’s studies in bladder cancer including the pivotal QUILT-3.032 study (NCT03022825), published in NEJM Evidence1 in November 2022.

Key Points: 
  • The BLA is supported by the results of ImmunityBio’s studies in bladder cancer including the pivotal QUILT-3.032 study (NCT03022825), published in NEJM Evidence1 in November 2022.
  • Of the nine subjects, two were deceased from causes other than bladder cancer and one was lost to follow-up.
  • Final clinical Results of Pivotal Trial of IL-15rαfc Superagonist N-803 with BCG in BCG-Unresponsive CIS and Papillary Non-Muscle Invasive Bladder Cancer (NMIBC).
  • Phase II/III Clinical Results of IL-15rαfc Superagonist N-803 with BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma in Situ (CIS) Patients.

Nucleix Bladder EpiCheck® Now Available in France via the Association Francaise d'Urologie (AFU) Registry for Surveillance of Recurrence of Bladder Cancer

Retrieved on: 
Monday, October 23, 2023
Biotechnology, Health, Oncology, Biometrics, Medical Affairs Bureau, Bladder cancer, Incidence, Molecular biology, Genetic testing, Biomarker, Life, CE, Urology, Methylation, Disease, Urine, AFU, Risk, Recurrence, Urinary bladder, U.S. FDA, Cystoscopy, NPV, Cancer, Carcinoma, Liquid biopsy, NMIBC, Patient, Dietary supplement, Medical device, EU

Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced participation in the Association Francaise d'Urologie (AFU) Registry of the Therapeutic Management and Follow-Up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU).

Key Points: 
  • Nucleix , a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced participation in the Association Francaise d'Urologie (AFU) Registry of the Therapeutic Management and Follow-Up of Non-Muscle-Invasive Bladder Cancer (TVNIM-AFU).
  • The registry will evaluate the diagnostic performance of selected urine biomarkers in French patients and compare them to the results of bladder endoscopies (cystoscopy) performed over two years for routine follow-up of NMIBC.
  • The registry is open to all urologists who are members of the AFU to include patients undergoing tumor resection.
  • Bladder EpiCheck testing will be performed by Inovie Gen-Bio, a network that conducts molecular biology and genetic testing across France.

Foundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Knowledge, Research, Cholangiocarcinoma, CTX, ESMO, Progression-free survival, CUP, Foundation Medicine, MD, Bladder cancer, Doctor of Philosophy, PET, Neoplasm, Abstract, Liquid, Booths, BTC, University, Roche, Safety, Cancer, European Society for Medical Oncology, Liquid biopsy, MD Anderson Cancer Center, Patient, Prognosis, DNA, Pharmaceutical industry, Medical imaging

Foundation Medicine, Inc ., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.

Key Points: 
  • Foundation Medicine, Inc ., today announced that the company will present 11 abstracts demonstrating the value of high-quality biomarker tests to inform cancer care at the 2023 European Society for Medical Oncology (ESMO) Annual Meeting from October 20-24 in Madrid, Spain.
  • In patients with CUP, the tumor of origin is unknown, which has historically made targeted treatment challenging.
  • As a result, there has been little progress in improving the poor outcomes for these patients.
  • Follow Foundation Medicine on Twitter and LinkedIn for more updates from #ESMO23 and visit us in person at Booths 727 and 728.

Predicine announces six studies showcasing MRD and liquid biopsy innovations at ESMO 2023

Retrieved on: 
Tuesday, October 17, 2023
Congress, Gene expression, Medicine, Breast cancer, NGS, CDX, Health, Oncology, ESMO, Sequence, Nucleic acid thermodynamics, Bladder cancer, MRD, European Society for Medical Oncology, Liquid biopsy, Medical imaging

HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

Key Points: 
  • HAYWARD, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Predicine, a pioneer in the liquid biopsy, announce its participation in the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
  • The company will present six compelling poster studies, unveiling the future of liquid biopsy solutions.
  • These poster presentations will shine a spotlight on Predicine’s groundbreaking liquid biopsy innovations, including PredicineBEACON™, a revolutionary solution for personalized and actionable minimal residual disease (MRD) analysis.
  • We look forward to engaging with the oncology community to explore the limitless possibilities of MRD in precision medicine."

GT Apeiron Announces Development Candidate Nomination of Brain Penetrant PRMT5 Inhibitor, GTA182, for the Potential Treatment of MTAP-Deleted Solid Cancers

Retrieved on: 
Tuesday, October 17, 2023
Senior, Cancer, Intelligence, GBM, Bladder cancer, PRMT5, IND, MTAP, Research fellow, SAN, Lung, Neoplasm, MTA, Glioblastoma, CNS, Investigational New Drug, Patient, Pharmaceutical industry, Medical imaging, Biology, Apeiron

SAN FRANCISCO and SHANGHAI, China, Oct. 17, 2023 (GLOBE NEWSWIRE) -- GT Apeiron Therapeutics (‘Apeiron’), a biopharmaceutical company harnessing the power of artificial intelligence to develop targeted precision therapies for unmet medical needs, today announced the development candidate nomination of GTA182, a brain penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor that exhibits methylthioadenosine (MTA) cooperativity resulting in high selectivity for MTAP-deleted cancer cells while sparing MTAP-expressing non-cancer cells. This selectivity is expected to provide a more effective and safer treatment option for patients with MTAP-deleted cancers.

Key Points: 
  • This selectivity is expected to provide a more effective and safer treatment option for patients with MTAP-deleted cancers.
  • GTA182 is brain penetrant and has demonstrated tumor growth inhibition and tumor regression in in vivo pre-clinical models of glioblastoma (GBM) as well as non-CNS murine cancer models with MTAP deletions.
  • Apeiron plans to file an Investigational New Drug (IND) application in mid-2024.
  • "The nomination of our wholly–owned GTA182 program as a candidate for clinical development represents another significant milestone for Apeiron and our commitment to developing innovative therapies for cancer patients with unmet medical needs," said Mingxi Li, Ph.D., Chief Executive Officer of Apeiron.

Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial

Retrieved on: 
Tuesday, October 17, 2023
Surgery, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Oncology, Congress, Confidence interval, Physician, NYSE, Lung cancer, Bristol Myers Squibb, Hope, Death, Research, Abstract, Disclosure, Risk, Disease, MD Anderson Cancer Center, European Society for Medical Oncology, Cancer, ESMO, University, Melanoma, EFS, IIA, Checkmate, EDT, Bladder cancer, Overalls, PCR, BMY, Patient, MPR, Pharmaceutical industry, NSCLC, Nivolumab

Additionally, neoadjuvant Opdivo and chemotherapy showed improvements in the secondary efficacy endpoints of pathologic complete response (pCR; 25.3% vs. 4.7%) and major pathologic response (MPR; 35.4% vs 12.1%).

Key Points: 
  • Additionally, neoadjuvant Opdivo and chemotherapy showed improvements in the secondary efficacy endpoints of pathologic complete response (pCR; 25.3% vs. 4.7%) and major pathologic response (MPR; 35.4% vs 12.1%).
  • Definitive surgery rates were 78% with the Opdivo-based regimen vs. 77% with chemotherapy and placebo, with complete resection achieved in 89% vs. 90% of patients, respectively.
  • “Over the past few years, we have witnessed incredible progress in the treatment of patients with non-metastatic non-small cell lung cancer.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -77T clinical trial.

Vesica Health Announces the Appointment of Recognized Industry Leaders to Newly Formed Board of Directors

Retrieved on: 
Tuesday, October 17, 2023
Quest Diagnostics, Breast cancer, Harvard University, HEALTH, Communications officer, USS, Liquid biopsy, Research, Quality of life, IVD, NL, USS Fletcher (DD-992), US, Swidler Berlin Shereff Friedman, National Institute for Public Health and the Environment, AkzoNobel, Invitae, Bladder cancer, Corporate development, PCR, Biotechnology, DE, FDA, Berlin, Ventana Medical Systems, Erasmus MC, Genomics, Morgan Stanley Wealth Management, Public health, Sale, International law, Vaccine, General counsel, RIVM, Hematuria, Labcorp, Independent, Duke University, Executive, Roche, Patient, Management, Vesica, EU

"It is with great pleasure that we announce the appointment of Dr. Jan Groen, Mark McDonough, and Joe Sollee to our Board of Directors.

Key Points: 
  • "It is with great pleasure that we announce the appointment of Dr. Jan Groen, Mark McDonough, and Joe Sollee to our Board of Directors.
  • "Based on my experience, Vesica has a singular opportunity to not only take market share but drive widespread clinical adoption of its AssureDx test."
  • "Vesica is uniquely positioned with an impressive portfolio of intellectual property issued both domestically and internationally," commented Joe Sollee.
  • "Speaking on behalf of my fellow Board members, we are excited to be joining Vesica's Board at this important time for the company.

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Monday, October 16, 2023
Neoplasm, DNA repair, Biomarker, PDX, Proteomics, ACRV, Development, AACR, DNA, Cancer, AUC, Medicine, Endometrial cancer, Sensitivity, FDA, Therapy, Ovarian cancer, CHK2, Patient, Bladder cancer, Conference, Poster, AP3, Pharmaceutical industry, Mastic (plant resin), Medical imaging

WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) --  Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, announced data highlighting its AP3 approach to identify and evaluate biomarkers for its OncoSignature assay designed specifically to predict sensitivity to ACR-368, the company’s selective small molecule inhibitor targeting CHK1 and CHK2, currently in registrational-intent Phase 2 clinical trials. The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.

Key Points: 
  • The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week.
  • “We leverage this distinctive capability to create drug-tailored OncoSignature assays as a companion diagnostic aiming to identify and treat patients most likely to benefit from treatment.
  • Biomarker candidates were initially evaluated through pathway reconstitution and in cellular functional assays, after which they were assembled into the ACR-368 OncoSignature assay for further functional validation.
  • These data support the use of the company’s ACR-368 OncoSignature assay in its ongoing registrational-intent Phase 2 clinical trials, and demonstrate the distinctive, practical application of the company’s AP3 platform.

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

Retrieved on: 
Sunday, October 15, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Congress, Phagocytosis, Tumor microenvironment, Hepatocellular carcinoma, NSCLC, Safety, Lung cancer, Interim, Grenfell Tower Inquiry Phase 2, Cancer, ESMO, MHC-II, Nivolumab, Nature Communications, Bladder cancer, European Society for Medical Oncology, ASCO, Neoplasm, Macrophage, Cytokine, Antigen, Chemokine, HCC, Patient, Oxidative stress, Vaccine

CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.

Key Points: 
  • CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.
  • The data are the first to show that GDF-15 has an inhibitory effect on the activation of M1 macrophages.
  • These specific myeloid lineage immune cells are central to the initiation of immune responses, including the secretion of pro-inflammatory cytokines and chemokines, presentation of antigens as well as direct antitumor cytotoxicity.
  • Overall, the results indicate that GDF-15 counteracts myeloid immune cell activation, supporting the generation of an immune-evasive tumor microenvironment, an important feature in therapy resistance.